← Back to all trials
Not Yet Recruiting
NCT07658846
Hippo-Related Competing Endogenous RNA (ceRNA) Network Dysregulation and In Vitro Fertilization (IVF) Outcomes in Women With Diminished Ovarian Reserve
Conditions: Diminished Ovarian Reserve, Female Infertility, In Vitro Fertilization
Sex: Female
Ages: 18 Years – 40 Years
Healthy volunteers: No
Enrollment: 70
Sponsor: Assiut University
Location: Faculty of Medicine, Assiut University Asyut
Summary
Diminished Ovarian Reserve (DOR) is an important cause of female infertility and is associated with poor ovarian response and lower pregnancy rates during In Vitro Fertilization (IVF). The molecular mechanisms underlying impaired follicular development in DOR remain incompletely understood. Increasing evidence suggests that non-coding RNAs and components of the Hippo signaling pathway play important roles in granulosa cell proliferation, apoptosis, and follicular development.
This prospective observational cohort study aims to investigate the expression of the long non-coding RNA (lncRNA) Nuclear Paraspeckle Assembly Transcript 1 (NEAT1), microRNA (miRNA)-181a-5p, Hippo pathway components including Yes-Associated Protein 1 (YAP1) and Connective Tissue Growth Factor (CTGF), and Insulin-Like Growth Factor 1 (IGF1) in follicular fluid-derived cells from women with DOR undergoing IVF compared with women with normal ovarian reserve. The study will also evaluate relationships among these molecular markers and IVF outcomes, including oocyte quality, number of retrieved oocytes, and embryo developmental potential.
Eligibility Criteria
Inclusion Criteria:
* Women undergoing In Vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI) cycles.
* Infertility duration of at least one year
* Primary or secondary infertility.
Exclusion Criteria:
* Polycystic Ovary Syndrome (PCOS)
* Endometriosis.
* Ovarian tumors or malignancy.
* Severe systemic diseases affecting fertility.
* Metabolic syndrome.
* Connective tissue disorders.
* Hormonal therapy within the last three months.
* Refusal to participate.
Source: ClinicalTrials.gov (NCT07658846). StuddyBuddy aggregates publicly available trial information.